Funder: National Institutes of Health (NIH)
Due Dates: November 20, 2025 (Full application)
Funding Amounts: Up to $300,000 direct costs/year (R61, 2 years) and up to $471,000 direct costs/year (R33, up to 3 years); max 5 years total.
Summary: Supports multidisciplinary research to develop or improve technologies, drugs, devices, or clinical practices that enhance fertility outcomes in patients facing infertility, with emphasis on advancing innovations for assisted reproductive technologies (ART).
Key Information: R61/R33 phased award; clinical trials allowed only in R33 phase; strict milestone requirements for transition; foreign organizations eligible but foreign subawards not allowed.